E-PAUse: Encouraging Proper Antibiotic Use in Outpatient Setting

Drug Use Clinical Trial

— E-PAUse  

Official title:

E-PAUse: Encouraging Proper Antibiotic Use in Outpatient Setting

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06135376
• Other study ID #: MRC-01-23-076
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2023
• Est. completion date: April 30, 2026

Study information

• Verified date: November 2023
• Source: Hamad Medical Corporation
• Contact: Adeel A. Butt, MBBS, MS
• Phone: +97433311228
• Email: aabutt[@]hamad.qa
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Specific Aim 1: To determine the knowledge, attitude, and practice (KAP) of PHCC physicians regarding appropriate prescription of antibiotics in the outpatient setting.

Hypothesis 1a: PHCC physicians will have adequate theoretical knowledge regarding use of antibiotics for upper respiratory tract infections.

Hypothesis 1b: Despite adequate theoretical knowledge, fear of complications of untreated infection and patient demand and expectations will drive inappropriate antibiotic prescription for upper respiratory tract infections

Specific Aim 2: To test the effectiveness of a comprehensive multi-component intervention in a cluster randomized trial upon rate of antibiotics prescription for upper respiratory tract infections in individuals aged > 2 years presenting to primary care by PHCC physicians Hypothesis 2: Compared with a single intervention, a comprehensive multi-component intervention package will be associated with a significant reduction in inappropriate antibiotic prescription.

Investigators will conduct this study in the Primary Healthcare Center (PHCC) setting in Qatar. Investigators will identify four large PHCCs from the existing active centers. The study has 2 parts. Part 1 corresponds to specific aim 1 and comprises of a KAP survey which will be carried out in all four PHCCs and will include all physicians. Part 2 corresponds to specific aim 2 and is a cluster randomized clinical trial in which Investigators will randomize the four PHCCs into two groups.

First group (2 PHCCs) will receive training in appropriate documentation of infections and antibiotics prescription and will continue to provide usual care. Second group (2 PHCCs) will receive the comprehensive multi-component intervention, which consists of four elements:

1. Option for deferred prescription fulfilment;

2. Education of staff regarding appropriate uses of antibiotics,

3. algorithm-driven decision support tool,

4. Feedback on individual and group performance.

Description:

As above.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600000
• Est. completion date: April 30, 2026
• Est. primary completion date: April 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 120 Years

Eligibility

Inclusion Criteria:

• Patients >2 years old presenting to any of the selected PHCCs (rationale: signs and symptoms of bacterial infection in very young children are more non-specific and empiric antibiotics are often indicated due to serious consequences of unrecognized and untreated bacterial infections)

• Presenting with acute (<1 week of symptoms) upper respiratory tract infection (URTI) like illness including

• common cold/acute rhinitis/nasopharyngitis

• laryngitis/laryngotracheitis

• Acute bronchitis

• acute otitis media

• influenza (confirmed or influenza-like illness)

• pharyngitis/tonsillitis

• acute sinusitis

Exclusion Criteria:

• Known immune compromised status, e.g., cystic fibrosis, cancer, organ transplant recipient.

• On immune suppressive therapy for any duration (e.g., steroids, disease modifying antirheumatic agents; cancer chemotherapy, anti-rejection drugs, etc.) in one year prior to presentation

• Known or diagnosed bacterial cause of infection.

• Severe systemic illness requiring referral to the emergency department or hospitalization within 24 hours of presentation

• Known or suspected chronic obstructive pulmonary disease. Asplenic patients (anatomic or functional)

Related Conditions & MeSH terms

• Drug Use

Intervention

Behavioral:
• comprehensive multi-component interventions
It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.

Locations

Country	Name	City	State
Qatar	PHCC	Doha

Sponsors (2)

Lead Sponsor	Collaborator
Hamad Medical Corporation	Primary Health Care Corporation, Qatar

Country where clinical trial is conducted

Qatar, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total number of antibiotics courses prescribed for URTIs	For each recorded diagnosis of URTI, investigators will count the number of persons who received an antibiotic prescription. All prescriptions regardless of drug, dose, route of administration and duration will be counted. Only one prescription per 30-day period will be counted to exclude those with ongoing, evolving, or unresolved infection.	36 months
Primary	Proportion of antibiotics prescription dispensed for an inappropriate use	For each antibiotic prescription written for a URTI diagnosis, investigators will determine the appropriateness of antibiotics based on our previously published criteria.	36 months
Secondary	Rates of hospitalization in 28 days after the PHCC visit	Number of hospitalizations within 28 days of the index visit	36 months
Secondary	Rates of ED visits in 28 days after the PHCC visit	Number of ED visits within 28 days of the index visit	36 months